- Conditions
- Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT)
- Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1633–1656
of 12,241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult T-cell Leukemia-Lymphoma
- Interventions
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
- Biological · Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
- Interventions
- L-citrulline, Plasmalyte A
- Drug
- Lead sponsor
- Asklepion Pharmaceuticals, LLC
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
- Conditions
- Acne Vulgaris
- Interventions
- ASC-J9 cream, placebo
- Drug
- Lead sponsor
- AndroScience Corp
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Fremont, California • San Diego, California • Boise, Idaho + 7 more
- Conditions
- Tuberous Sclerosis, Lymphangioleiomyomatosis
- Interventions
- Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure
- Procedure · Genetic · Other
- Lead sponsor
- National Tuberous Sclerosis Association
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2050
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 19 more
- Conditions
- Dental Caries
- Interventions
- Ozone treatment, Placebo treatment
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 10 Years to 40 Years
- Enrollment
- 394 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts • Buffalo, New York
- Conditions
- Chronic Kidney Disease
- Interventions
- MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Drug · Device
- Lead sponsor
- MediBeacon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Edgewater, Florida • Chicago, Illinois • Saint Paul, Minnesota + 2 more
- Conditions
- Breast Cancer
- Interventions
- aldesleukin, filgrastim, sargramostim, therapeutic autologous lymphocytes, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Biological · Drug
- Lead sponsor
- Roger Williams Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Fat Disorder
- Interventions
- eon™ FR 1064 nm device
- Device
- Lead sponsor
- Dominion Aesthetic Technologies, Inc.
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Sacramento, California • Altamonte Springs, Florida • Miami, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Structural Image, Functional Image, Digit Span subtest, Brief Test of Attention, Trail Making Test (Parts A & B), Auditory Consonant Trigrams Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, The Center for Epidemiological Study-Depression, The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4, Blood draw
- Diagnostic Test · Behavioral · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • New York, New York
- Conditions
- Hepatorenal Syndrome
- Interventions
- Ifetroban Injection, Placebo
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
- Conditions
- Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases
- Interventions
- Harvesting and Implantation of SVF
- Procedure
- Lead sponsor
- Ageless Regenerative Institute
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Aventura, Florida
- Conditions
- Sudden Cardiac Arrest, Emergency Care
- Interventions
- Standard of Care
- Diagnostic Test
- Lead sponsor
- Heartstream US LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission, Adult Erythroleukemia (M6a), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Philadelphia Chromosome Negative Chronic Myelogenous Leukemia, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, total-body irradiation, fludarabine phosphate, busulfan, allogeneic hematopoietic stem cell transplantation
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 39
- States / cities
- Berkeley, California • Duarte, California • La Jolla, California + 30 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
- Interventions
- GRN1005
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 9
- States / cities
- La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more
- Conditions
- Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
- Interventions
- TC-5214
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Multiple Dose of 225Ac-J591 at 45 KBq/kg, Multiple Dose of 225Ac-J591 at 55 KBq/kg, Multiple Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg, Fractionated Dose of 225Ac-J591 at 55 KBq/kg, Fractionated Dose of 225Ac-J591 at 60 KBq/kg, Fractionated Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg (Prior 177Lu-PSMA-RL), Fractionated Dose of 225Ac-J591 at 50 KBq/kg (Prior 177Lu-PSMA-RL), 68Ga-PSMA-HBED-CC injection
- Drug · Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Brooklyn, New York • New York, New York
- Conditions
- Basal Cell Nevus Syndrome, Gorlin's Syndrome
- Interventions
- Vismodegib, Aminolevulinic acid %20 topical solution
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Oakland, California • New York, New York
- Conditions
- Arterial Occlusive Diseases
- Interventions
- alfimeprase
- Drug
- Lead sponsor
- ARCA Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Malignant Melanoma
- Interventions
- Drug cocktail, RO5185426
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
- Device
- Lead sponsor
- Cervel Neurotech, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Lebanon, New Hampshire + 3 more